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Résumé en
anglais
Diffuse gliomas are classified according to the 2016 WHO Classification of Tumors of
the Central Nervous System, which now defines entities by both histology and
molecular features. Somatostatin receptor subtype 2A (SSTR2A) expression has been
reported in various solid tumors as associated with favorable outcomes. Its expression
has been reported in gliomas with uncertain results regarding its prognostic value. The
objective of this study was to assess the prognostic impact of SSTR2A protein
expression in a large cohort of grade III and IV gliomas classified according to the
updated 2016 WHO classification. We further validated our result with an independent
cohort of low grade glioma using dataset generated by The Cancer Genome Atlas
(TCGA) Research Network.We analyzed clinical and molecular data from 575 patients.
SSTR2A protein expression was evaluated using immunohistochemistry on tissue
microarrays. High expression of SSTR2A protein associated with the anaplastic
oligodendroglioma IDH-mutant and 1p/19q-codeleted subgroup (p < 0.001). Among
these tumors, SSTR2A protein expression was significantly associated with a lower
proliferative index, the absence of microvascular proliferation and the absence of
necrosis (p < 0.001). Furthermore SSTR2A protein expression associated with better
overall survival (p = 0.007) and progression-free survival (p = 0.01) in both univariate
and multivariate analysis when adjusted by the age, the presence of necrosis and the
mitotic index. Similar results were obtained regarding SSTR2 mRNA expression in the
TCGA low grade glioma, subtype IDH-mutant and 1p/19q-codeleted, dataset.SSTR2A
might represent an attractive biomarker and therapeutic target in anaplastic
oligodendroglioma IDH-mutant and 1p/19q-codeleted specific subgroup.
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